PVI Alone vs PVI With Posterior Wall Isolation for Pulse-Field Ablation in Persistent AF
POBI-PFA
Comparison of Pulmonary Vein Isolation Alone Versus Pulmonary Vein Isolation With Posterior Wall Isolation for Pulse-Field Ablation in Persistent Atrial Fibrillation: A Prospective Randomized Controlled Trial
1 other identifier
interventional
214
1 country
1
Brief Summary
To date, no optimal treatment has been established to improve outcomes in patients with persistent atrial fibrillation. The safety and efficacy of pulsed-field ablation (PFA) have been demonstrated in several studies, and its clinical application is expanding. \- In patients with persistent atrial fibrillation, can the addition of posterior wall isolation (PWI) following pulmonary vein isolation (PVI) using PFA reduce recurrence? Participants will:
- Undergo either PVI alone or PVI with additional left atrial posterior wall isolation (PWI)
- Visit the clinic to assess for recurrence of atrial tachyarrhythmias
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started May 2025
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 13, 2025
CompletedFirst Posted
Study publicly available on registry
April 16, 2025
CompletedStudy Start
First participant enrolled
May 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 1, 2027
April 16, 2025
April 1, 2025
2 years
March 13, 2025
April 8, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Recurrence of atrial tachyarrhythmia
Clinical recurrence rate of atrial fibrillation within one year after the procedure.
Within one year from the time of enrollment, excluding the first three months after the procedure
Secondary Outcomes (5)
Peri-procedural complication
Within one year from the time of enrollment
Total procedure time
Periprocedural
Length of hospital stay
Within one year from the time of enrollment
patient satisfaction
Within one year from the time of enrollment
Atrial fibrillation burden
Within one year from the time of enrollment
Study Arms (2)
Additional Left Atrial Posterior Wall Ablation Group
ACTIVE COMPARATORAfter pulmonary vein isolation, electrical isolation of the left atrial posterior wall is performed using a pulsed-field ablation catheter with EGM-guided ablation.
Pulmonary Vein Isolation (PVI) only Group
PLACEBO COMPARATORElectrical isolation of all four pulmonary veins is performed using a pulsed-field ablation catheter.
Interventions
1. Pulmonary vein isolation (PVI) is performed as the primary procedure. 2. After PVI, direct current (DC) cardioversion is performed to restore normal sinus rhythm. If the patient converts to sinus rhythm, they are randomly assigned to either the PVI-only group or the additional left atrial posterior wall ablation group. 3. Patients who fail to convert to sinus rhythm after DC cardioversion are excluded from randomization.
1. Additional left atrial posterior wall ablation is performed. 2. Complete electrical isolation of the entire left atrial posterior wall is confirmed (posterior box lesion isolation must be achieved). 3. Post-procedural rhythm monitoring follows the study protocol.
1. If atrial fibrillation triggers are identified with isoproterenol infusion, additional focal ablation is performed. 2. Post-procedural rhythm monitoring follows the study protocol.
Eligibility Criteria
You may qualify if:
- Patients eligible for catheter ablation according to existing clinical guidelines
- Those without clinically significant structural heart disease (e.g., severe mitral regurgitation)
- Those without contraindications to anticoagulation therapy
You may not qualify if:
- Atrial fibrillation associated with severe congenital heart disease or structural heart disease
- Patients with contraindications to general anesthesia or sedation for the procedure
- History of prior cardiac surgery (e.g., Maze procedure, coronary artery bypass grafting)
- History of atrial fibrillation catheter ablation within the past 12 months
- Patients with severe left ventricular dysfunction (left ventricular ejection fraction \<30%)
- Patients with active internal bleeding
- Patients with contraindications to anticoagulation therapy and antiarrhythmic drugs
- Valvular atrial fibrillation (e.g., mitral stenosis \> grade 2, mechanical valve, prior mitral valve repair)
- Patients with severe comorbid conditions
- Patients with an expected survival of less than one year
- Patients with drug or alcohol addiction
- Pregnant or breastfeeding women
- Any other conditions deemed by the investigator to make the patient unsuitable for study participation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ewha Womans University Mokdong Hospitallead
- Ewha Womans University Seoul Hospitalcollaborator
- Korea University Anam Hospitalcollaborator
- Ajou University School of Medicinecollaborator
- Seoul National University Bundang Hospitalcollaborator
- Kangbuk Samsung Hospitalcollaborator
- Hanyang University Seoul Hospitalcollaborator
- Asan Medical Centercollaborator
- Wonkwang University Hospitalcollaborator
- Korea University Guro Hospitalcollaborator
- Severance Hospitalcollaborator
- Eunpyeong St. Mary's Hospitalcollaborator
Study Sites (1)
Ewha Womans University Mokdong Hospitoal
Seoul, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 13, 2025
First Posted
April 16, 2025
Study Start
May 1, 2025
Primary Completion (Estimated)
May 1, 2027
Study Completion (Estimated)
October 1, 2027
Last Updated
April 16, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share
Individual participant data (IPD) will not be shared due to concerns regarding patient confidentiality and the lack of specific consent for data sharing obtained during the study enrollment process.